Patents by Inventor Roberta Cannella

Roberta Cannella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190177296
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Application
    Filed: December 21, 2018
    Publication date: June 13, 2019
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • Patent number: 10208073
    Abstract: Disclosed is a solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium (fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone and its application in methods for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: February 19, 2019
    Assignee: Helsinn Healthcare SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J Stella
  • Publication number: 20180256567
    Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    Type: Application
    Filed: March 16, 2018
    Publication date: September 13, 2018
    Inventors: Fabio TRENTO, Sergio CANTOREGGI, Giorgia ROSSI, Roberta CANNELLA, Daniele BONADEO
  • Publication number: 20180193262
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Application
    Filed: September 19, 2017
    Publication date: July 12, 2018
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Alberto Macciocchi, Andrew Miksztal, Thomas Malefyt, Kathleen M. Lee, Carmine Panuccio
  • Publication number: 20180194788
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Application
    Filed: January 18, 2018
    Publication date: July 12, 2018
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
  • Patent number: 9943515
    Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: April 17, 2018
    Assignee: Helsinn Healthcare SA
    Inventors: Fabio Trento, Sergio Cantoreggi, Giorgia Rossi, Roberta Cannella, Daniele Bonadeo
  • Patent number: 9908907
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: March 6, 2018
    Assignee: Helsinn Healthcare SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J Stella
  • Publication number: 20170348335
    Abstract: Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
    Type: Application
    Filed: June 2, 2017
    Publication date: December 7, 2017
    Inventors: Alessio Venturini, Roberta Cannella
  • Publication number: 20170050993
    Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.
    Type: Application
    Filed: June 28, 2016
    Publication date: February 23, 2017
    Applicant: Helsinn Healthcare SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J Stella
  • Publication number: 20170042807
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Application
    Filed: August 18, 2016
    Publication date: February 16, 2017
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Alberto Macciocchi, Andrew Miksztal, Thomas Malefyt, Kathleen M. Lee
  • Publication number: 20160317440
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Application
    Filed: July 14, 2016
    Publication date: November 3, 2016
    Applicant: Helsinn Healthcare SA
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Andrew Miksztal, Thomas Malefyt, Kathleen M. Lee
  • Publication number: 20160296510
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Application
    Filed: June 22, 2016
    Publication date: October 13, 2016
    Applicant: Helsinn Healthcare SA
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Alberto Macciocchi, Andrew Miksztal, Thomas Malefyt, Kathleen M Lee
  • Patent number: 9457021
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: October 4, 2016
    Assignee: Helsinn Healthcare SA
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Alberto Macciocchi, Andrew Miksztal, Thomas Malefyt, Kathleen M Lee
  • Patent number: 9457020
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: October 4, 2016
    Assignee: Helsinn Healthcare SA
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Andrew Miksztal, Thomas Malefyt, Kathleen M Lee
  • Patent number: 9439854
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: September 13, 2016
    Assignee: Helsinn Healthcare SA
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Alberto Macciocchi, Andrew Miksztal, Thomas Malefyt, Kathleen M Lee
  • Patent number: 9403772
    Abstract: Compounds and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor, based on 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)3yridine-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: August 2, 2016
    Assignee: HELSINN HEALTHCARE SA
    Inventors: Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J Stella
  • Publication number: 20160136162
    Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    Type: Application
    Filed: January 21, 2016
    Publication date: May 19, 2016
    Applicant: Helsinn Healthcare SA
    Inventors: Fabio TRENTO, Sergio CANTOREGGI, Giorgia ROSSI, Roberta CANNELLA, Daniele BONADEO
  • Patent number: 9308266
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: April 12, 2016
    Assignees: HELSINN HEALTHCARE SA, ROCHE PALO ALTO LLC
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Alberto Macciocchi, Andrew Miksztal, Thomas Malefyt, Kathleen M Lee, Carmine Panuccio
  • Patent number: 9271975
    Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: March 1, 2016
    Assignee: HELSINN HEALTHCARE SA
    Inventors: Fabio Trento, Sergio Cantoreggi, Giorgia Rossi, Roberta Cannella, Daniele Bonadeo
  • Publication number: 20160000773
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Application
    Filed: September 16, 2015
    Publication date: January 7, 2016
    Applicants: Roche Palo Alto LLC
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Andrew Miksztal, Thomas Malefyt, Kathleen M. Lee